跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Glaxo Group Limited

首页临床试验发起方与机构Glaxo Group Limited

Glaxo Group Limited

Vantage Point Business Village, Mitcheldean, 英国

别名:

glaxo

glaxo smithkline

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

42

42 进行中

药物批准

14

批准总数

监管机构

3

监管机构数

成立时间

N/A

概览

试验阶段分布

暂无试验阶段数据

试验状态分布

进行中（未招募）

42

100.0%

相关临床试验

该机构主办的试验（42）

GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with febrile complicated lower urinary tract infections and acute pyelonephritis

进行中（未招募）

Dec 2011210 名受试者

Evaluation of immunogenicity and safety of two 2-dose Human Papillomavirusthe (HPV) vaccine schedules in 9-14 years old girls.

进行中（未招募）

Sep 20111428 名受试者

Study to test a new drug GSK1349572 for HIV patients with raltegravir or elvitegravir failure

进行中（未招募）

Sep 2011200 名受试者

``A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejaculation.`` - ND

进行中（未招募）

A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole CR 1-24mg administered once daily for 12 weeks in subjects with fibromyalgia.

进行中（未招募）

A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alternative dosing schedule at, 0, 1 and 12 months as compared to the standard dosing schedule at 0, 1 and 6 months in young healthy female subjects aged 15-25 years. - Immunogenicity and Safety Study of GSK Biologicals...

进行中（未招募）

Nov 2007800 名受试者

A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ND

进行中（未招募）

Jun 2007680 名受试者

A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative, Phase III Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo

进行中（未招募）

Jun 2007520 名受试者

第 1 页，共 6 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

1

药物批准

SFDA

Saudi Food and Drug Authority

5

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

8

药物批准

近期批准

CUTIVATE 0.005% ointment

BACTROBAN NASAL OINTMENT 2%

CUTIVATE 0.05% cream

BACTROBAN OINT 2%

IMIGRAN 6MG-0.5ML AMP

RELVAR ELLIPTA 92 MICROGRAMOS/22 MICROGRAMOS POLVO PARA INHALACION (UNIDOSIS)

AVAMYS 27,5 MICROGRAMOS/PULVERIZACION SUSPENSION PARA PULVERIZACION NASAL

AVAMYS 27,5 MICROGRAMOS/PULVERIZACION SUSPENSION PARA PULVERIZACION NASAL

Adefovir Dipivoxil

AVAMYS 27,5mcg/pulverizacion suspension para pulverizacion nasal

资讯

暂无资讯文章

本页目录

概览
相关临床试验42
药物批准14
资讯

返回机构列表